Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 17 |
| Active Pipeline (Recruiting Now) | 8 (2) |
| Completed vs Stopped Early | 3 / 6 (35.3%) |
| Median Closed Actual Enrollment | 54 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Children's Hospital Colorado | Aurora, CO | 4 |
| Vanderbilt University Medical Center | Nashville, TN | 3 |
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05345171 | Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency | Phase III | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Ultragenyx Pharmaceutical across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Ultragenyx Pharmaceutical Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.